Literature DB >> 23441238

Topical pimecrolimus 1% cream in the treatment of seborrheic dermatitis.

Grace K Kim1, James Del Rosso.   

Abstract

Seborrheic dermatitis is a multifactorial skin disease characterized by a chronic course with periods of exacerbation and remission. Although topical corticosteroids have been the mainstay of treatment, alternative therapies are often needed to avoid protracted use of topical corticosteroid therapy in order to avert side effects and to sustain control of the disorder. Topical pimecrolimus, a calcinuerin inhibitor, is a safe alternative for seborrheic dermatitis and is more ideal for long-term use. More specifically, topical pimecrolimus not only has an attractive safety profile with no risk of many of the potential side effects seen with topical corticosteroids, but also has favorable efficacy data, including more data on long-term use. This is a review of literature evaluating the efficacy and safety profile of topical pimecrolimus 1% cream for the treatment of seborrheic dermatitis.

Entities:  

Year:  2013        PMID: 23441238      PMCID: PMC3579486     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  35 in total

1.  Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus.

Authors:  Andreas Billich; Heinrich Aschauer; András Aszódi; Anton Stuetz
Journal:  Int J Pharm       Date:  2004-01-09       Impact factor: 5.875

2.  Pimecrolimus cream 1% is effective in seborrhoeic dermatitis refractory to treatment with topical corticosteroids.

Authors:  Paulo Rowilson Cunha
Journal:  Acta Derm Venereol       Date:  2006       Impact factor: 4.437

3.  Effects of Pityrosporum ovale on proliferation, immunoglobulin (IgA, G, M) synthesis and cytokine (IL-2, IL-10, IFN gamma) production of peripheral blood mononuclear cells from patients with seborrhoeic dermatitis.

Authors:  K Neuber; S Kröger; E Gruseck; D Abeck; J Ring
Journal:  Arch Dermatol Res       Date:  1996-08       Impact factor: 3.017

4.  Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry.

Authors:  J Faergemann; I M Bergbrant; M Dohsé; A Scott; G Westgate
Journal:  Br J Dermatol       Date:  2001-03       Impact factor: 9.302

5.  A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology.

Authors:  M Grassberger; T Baumruker; A Enz; P Hiestand; T Hultsch; F Kalthoff; W Schuler; M Schulz; F J Werner; A Winiski; B Wolff; G Zenke
Journal:  Br J Dermatol       Date:  1999-08       Impact factor: 9.302

6.  Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis.

Authors:  Richard G B Langley; Lawrence F Eichenfield; Anne W Lucky; Mark Boguniewicz; Nathalie Barbier; Robert Cherill
Journal:  Pediatr Dermatol       Date:  2008 May-Jun       Impact factor: 1.588

7.  Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.

Authors:  Ulrich Wahn; Jan D Bos; Mark Goodfield; Ruggero Caputo; Kim Papp; Ahmed Manjra; Attila Dobozy; Carle Paul; Stephen Molloy; Thomas Hultsch; Michael Graeber; Robert Cherill; Yves de Prost
Journal:  Pediatrics       Date:  2002-07       Impact factor: 7.124

Review 8.  Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy.

Authors:  Bethany A Cook; Erin M Warshaw
Journal:  Am J Clin Dermatol       Date:  2009       Impact factor: 7.403

9.  Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study.

Authors:  Michael Meurer; Regina Fölster-Holst; Gottfried Wozel; Gottfried Weidinger; Michael Jünger; Matthias Bräutigam
Journal:  Dermatology       Date:  2002       Impact factor: 5.366

10.  Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients.

Authors:  B R Allen; M Lakhanpaul; A Morris; S Lateo; T Davies; G Scott; M Cardno; M-E Ebelin; P Burtin; T J Stephenson
Journal:  Arch Dis Child       Date:  2003-11       Impact factor: 3.791

View more
  3 in total

Review 1.  [Eczematous disorders in adolescents].

Authors:  R Fölster-Holst
Journal:  Hautarzt       Date:  2016-04       Impact factor: 0.751

Review 2.  Eyebrow and Eyelash Alopecia: A Clinical Review.

Authors:  Betty Nguyen; Jamie Katy Hu; Antonella Tosti
Journal:  Am J Clin Dermatol       Date:  2022-10-02       Impact factor: 6.233

3.  High Staphylococcus epidermidis Colonization and Impaired Permeability Barrier in Facial Seborrheic Dermatitis.

Authors:  Qian An; Meng Sun; Rui-Qun Qi; Li Zhang; Jin-Long Zhai; Yu-Xiao Hong; Bing Song; Hong-Duo Chen; Xing-Hua Gao
Journal:  Chin Med J (Engl)       Date:  2017-07-20       Impact factor: 2.628

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.